Addiction Research Institute
Austin, Texas, 78712, United States
NCT Number: NCT07741825
Adapt and test the effectiveness of MBRP for substance use peer workers compared to a standard of care (referral to 12-step) control condition on substance use, relapse risk, and burnout among peers in a pilot hybrid type 1 trial.
The goal of this clinical trial is to learn if Mindfulness-Based Relapse Prevention can reduce substance use, relapse risk, and burnout among substance use peer workers. The objectives are to:
1. Identify the causes, consequences, and risk and protective factors for relapse among peer workers; 2. Identify peers' preferences related to MBRP content, structure, and delivery; 3. Adapt the MBRP intervention for peer workers; and 4. Assess the preliminary effectiveness and implementation outcomes of the adapted MBRP intervention.
Researchers will compare MBRP to referral to 12-step (standard of care) to see if MRBP works to reduce substance use, relapse risk, and burnout.
Participants will asked to:
* Participate in MBRP (8 weekly 2-hour virtual sessions) * Complete 4 surveys assessing well-being outcomes * Participate in 1 virtual interview about your experience
Trial opening soon.
Get Notified18 year–100 year
All sexes
Interventional
Not applicable
Austin, Texas, 78712, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
MBRP for peer workers consists of 8 weekly 2-hour virtual sessions.
Referral to 12-step programming
Time frame: From enrollment to 6 months
Saliva drug assays detecting the presence or absence of commonly used substances. Results are reported as positive or negative for each substance tested, with negative results indicating a better outcome.
Time frame: From enrollment to 6 months
A calendar-based interview assessing daily substance use over a specified recall period. Outcomes are reported as the number of days of substance use during the assessment period, with fewer days indicating a better outcome.
Time frame: From enrollment to 6 months
A 28-item; 7-point Likert-type scale assessing warning signs associated with relapse risk. Total scores range from 28 to 196, with higher scores indicating greater relapse risk (worse outcome).
Time frame: From enrollment to 6 months
A 30-item; 5-point Likert-type scale assessing professional quality of life across three 10-item subscales: Compassion Satisfaction, Burnout, and Secondary Traumatic Stress. Each subscale score ranges from 10 to 50. Higher Compassion Satisfaction scores indicate a better outcome, whereas higher Burnout and Secondary Traumatic Stress scores indicate worse outcomes.
Time frame: Immediately after the final intervention session
A 4-item; 5-point Likert-type scale assessing the perceived feasibility of an intervention. Total scores range from 4 to 20, with higher scores indicating greater perceived feasibility (better outcome).
Time frame: Immediately after the final intervention session
A 4-item; 5-point Likert-type scale assessing the perceived acceptability of an intervention. Total scores range from 4 to 20, with higher scores indicating greater perceived acceptability (better outcome).
Time frame: From enrollment to 6 months
A 28-item; 4-point Likert-type scale assessing coping strategies. The Brief COPE consists of 14 two-item subscales, each ranging from 2 to 8, with higher scores indicating greater use of that specific coping strategy. There is no overall total score.
Time frame: From enrollment to 6 months
A 36-item; 5-point Likert-type scale assessing difficulties with emotion regulation. Total scores range from 36 to 180, with higher scores indicating greater difficulties in emotion regulation (worse outcome).
Time frame: From enrollment to 6 months
A 10-item; 5-point Likert-type scale assessing perceived stress. Total scores range from 0 to 40, with higher scores indicating greater perceived stress (worse outcome).
Time frame: From enrollment to 6 months
A 15-item; 5-point Likert-type scale assessing trait mindfulness. Total scores range from 15 to 75, with higher scores indicating greater mindfulness (better outcome).
Time frame: From enrollment to 6 months
A 7-item; 7-point Likert-type scale assessing psychological inflexibility/experiential avoidance. Total scores range from 7 to 49, with higher scores indicating greater psychological inflexibility and experiential avoidance (worse outcome).
Time frame: From enrollment to 6 months
A 24-item; 5-point Likert-type scale assessing mental health symptoms and functioning. Total scores range from 0 to 4 (calculated as the mean of completed items), with higher scores indicating greater psychiatric symptoms and functional difficulties (worse outcome).
Time frame: From enrollment to 6 months
A 28-item; 4-point Likert-type scale assessing recovery capital across multiple domains. Total scores range from 28 to 112, with higher scores indicating greater recovery capital (better outcome).
Time frame: From enrollment to 6 months
A 9-item; 7-point Likert-type scale assessing work engagement. Total scores range from 0 to 54 (or a mean score ranging from 0 to 6), with higher scores indicating greater work engagement (better outcome).
Contact information is provided by the study sponsor or research team.
University of Texas at Austin
Other
Adapting and Pilot Testing Mindfulness-Based Relapse Prevention for Substance Use Peer Workers
Acronym: MBRP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04984837
Disease Attributes, Hemic and Lymphatic Diseases
Anderlecht, Belgium
View Trial DetailsNCT07563179
Acute Myeloid Leukemia, Disease Attributes
Shenzhen, Guangdong, China
View Trial DetailsNCT04689659
Disease Attributes, Hematologic Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT06125483
Disease Attributes, Hematologic Diseases
Suzhou, Jiangsu, China
View Trial Details